Defence Therapeutics (CSE:DTC; OTCQB:DTCFF; FSE:DTC) announced that it has received a “no objection letter” (NOL) from Health Canada authorizing the company to proceed with a Phase I trial of intratumoral administration ACCUM-002 (AccuTOX) as a monotherapy in combination with Opdualag in patients with unresectable stage IIIB and IV melanoma.
Defence has reported planning for the Phase I study has commenced and will likely be conducted in Quebec and Ontario, Canada.
In a statement, Sebastien Plouffe, CEO of Defence Therapeutics, said, “AccuTOX is Defence’s flagship asset in the anti-cancer therapeutics field, and this Phase I clinical trial shall demonstrate and confirm primarily its safety and secondly its potency.”
The global cancer immunotherapy market size was estimated at $125.73 billion in 2023 and projected to increase $280.11 billion by 2033, with a CAGR of 8.34% from 2024 to 2033, according to Vision Research Reports.
